Sarcopenia and Related Factors in COVID-19 Following Intensive Care
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sarcopenia
- Sponsor
- Koç University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Hand grip strength
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
The primary aim of this study is to evaluate the patients who had pneumonia or severe acute respiratory distress syndrome (ARDS) due to COVID-19 in terms of sarcopenia and related factors following Intensive Care Unit (ICU).
The patients who had COVID-19 infection in the ICU and the patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period will be compared in terms of sarcopenia.
Detailed Description
Patients with acute respiratory distress syndrome (ARDS) could develop muscle weakness associated with impairment of physical function defined as intensive care unit acquired weakness. Significant muscle loss occurs in the first week of the Intensive Care Unit (ICU) hospitalizations due to acute respiratory failure. Patients lose 18 percent of their body weight when discharged from the ICU. The presence of sepsis is known as the hypercatabolic process for the muscles. Hypophosphatemia and hypomagnesemia can cause respiratory muscle weakness. Fever and inflammation, use of muscle relaxant or sedatives may also cause muscle loss in intensive care during this period. COVID-19 is an acute infection with a high risk of enormous cytokine storm exacerbating the clinical condition in acute respiratory distress syndrome and is thought to further increase the risk of muscle weakness. The patients will be evaluated for hand grip strength, calf circumference measurement, 'Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls' (SARCF), SarQoL, timed up and go test, sit to stand test, and Short form-36.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with ARDS or severe pneumonia due to COVID-19 hospitalized in intensive care unit
- •\> 18 years old
- •Age and gender matched patients admitted to the 'Physical Medicine and Rehabilitation' clinic for control group
Exclusion Criteria
- •Other diseases that may cause sarcopenia (cancer, non-respiratory organ failure and heart, liver or kidney failure)
- •Neurological diseases that may cause sarcopenia (stroke, spinal cord injury, muscle diseases)
Outcomes
Primary Outcomes
Hand grip strength
Time Frame: 12 months
Hand grip strength is an indicator of overall muscle strength that predicts mortality in older patients. Hand grip strength was measured using a handheld dynamometer according to the instructions of the American Society of Hand Therapists.Patients were seated placing their arms by their sides with the elbow flexed to 90°, the forearm mid-prone, and the wrist in neutral position. Patients were asked to grip the dynamometer with maximal effort using standard verbal encouragement. Three trials were performed in the dominant hand with a 30 sec rest between trials and the highest value was recorded in kg. The cut-off values of grip strength is 28.6 kg in men and 16.4 kg in women.
Secondary Outcomes
- Calf circumference measurement(12 months)
- Short form - 36(12 months)
- SARC-F (Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls)(12 months)
- Sarcopenia Quality of Life (SarQoL )(12 months)
- Sit to stand test(12 months)
- Timed up and go test(12 months)